Adipose-derived mesenchymal stem cell as potent tool for inflammatory bowel disease treatment

Introduction Nowadays, cell therapy has opened a new window for treating inflammatory bowel disease (IBD). Adipose derived stem cells (ASCs) have shown significant anti-inflammatory, therapeutic and trophic potential. In this study, we have designed an experiment to assess combination therapy of ASCs and sulfasalazine (as a reference drug for IBD treatment) on experimental colitis model. Methods Acute colitis in rat induced by intracolonic administration of 50 mg /kg trinitrobenzenesulfonic acid (TNBS). Rats were divided into five groups: control group, TNBS group, sulfasalazine group, ASC group, ASC + sulfasalazine group. Groups with ASC received a single intra-peritoneal injection of ASCs 3 hours after colitis induction and groups with Sulfasalazine received a daily dose of sulfasalazine (30 mg/ kg). Body weight, disease activity index (DAI), colon length, colon weight to length ratio were measured. Results Coadministration of ASC + sulfasalazine significantly suppressed TNBS‑induced body weight loss, colon length shortening and decreased the colon weight to length ratio. Conclusion The results of this study suggested that ASCs as new promising therapeutic option for inflammatory diseases are able to show potent anti-inflammatory effects on colitis when co-administered with low dose of sulfasalazine.

کلیدواژه ها:

Cell Therapy ، IBD ، Mesenchymal Stem Cells ، Combination Therapy